Efavirenz
HIV Infections
The Cleveland ClinicSmall moleculePhase 4 / ApprovedDormant
BBB
77/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 74/ 100
- Competitive Position
- 81/ 100
Competitive context
62 Active assets in the HIV Infections cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltegravir Helsinki University Central Hospital | Phase 4 | A |
ZIDOVUDINE International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Phase 4 | BBB |
Ganciclovir | Phase 4 | BBB |
Dolutegravir Instituto Mexicano del Seguro Social | Phase 4 | BBB |
RITONAVIR Giovanni Di Perri | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Efavirenz is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →